Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

518 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH Jr. Sandborn WJ, et al. Among authors: feagan bg. Gastroenterology. 1999 Sep;117(3):527-35. doi: 10.1016/s0016-5085(99)70445-2. Gastroenterology. 1999. PMID: 10464128 Clinical Trial.
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR; CDP571 Crohn's Disease Study Group. Sandborn WJ, et al. Among authors: feagan bg. Gastroenterology. 2001 May;120(6):1330-8. doi: 10.1053/gast.2001.24042. Gastroenterology. 2001. PMID: 11313302 Clinical Trial.
The effectiveness of budesonide therapy for Crohn's disease.
Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. Kane SV, et al. Among authors: feagan bg. Aliment Pharmacol Ther. 2002 Aug;16(8):1509-17. doi: 10.1046/j.1365-2036.2002.01289.x. Aliment Pharmacol Ther. 2002. PMID: 12182751 Free article. Review.
Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.
Panaccione R, Fedorak RN, Aumais G, Bernstein CN, Bitton A, Croitoru K, Enns R, Feagan B, Fishman M, Greenberg G, Griffiths A, Marshall JK, Rasul I, Sadowski D, Seidman E, Steinhart H, Sutherland L, Walli E, Wild G, Williams CN, Zachos M; Canadian Association of Gastroenterology. Panaccione R, et al. Can J Gastroenterol. 2004 Aug;18(8):503-8. doi: 10.1155/2004/670161. Can J Gastroenterol. 2004. PMID: 15372114 No abstract available.
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. Feagan BG, et al. Aliment Pharmacol Ther. 2005 Feb 15;21(4):373-84. doi: 10.1111/j.1365-2036.2005.02336.x. Aliment Pharmacol Ther. 2005. PMID: 15709987 Free article. Clinical Trial.
518 results